rld2302
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 2, 2024 (NCT06346184)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06518122 | Phase 1 | Aug 31, 2024 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT06357910 | Phase 1 | May 17, 2024 | Hanmi Pharmaceutical, Jeonbuk National University |
| NCT06346184 | Phase 1 | May 2, 2024 | Hanmi Pharmaceutical, Jeonbuk National University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 3 | 3 | 1 | 2024 |
| Jeonbuk National University | Academic/Hospital | 3 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1